Core Viewpoint - Huajian Medical (01931) announced the appointment of Ms. Tai Yang as an executive director, effective from October 20, 2025 [1] Summary by Relevant Sections - Board Changes: - Ms. Tai Yang will no longer serve as a member of the remuneration committee, with Mr. Zhang Jianlei appointed as a member [1] - Ms. Tai Yang has resigned as the chairman of the nomination committee but will remain a member, while Mr. Zhang Jianlei has been appointed as the chairman of the nomination committee [1]

Core Viewpoint - Huajian Medical (01931.HK) announced the appointment of Tai Yang as an executive director, effective from October 20, 2025 [1] Group 1 - Tai Yang has been transitioned from an independent non-executive director to an executive director [1]

華 檢 醫 療 控 股 有 限 公 司 董 事 會（「董事會」）成 員 載 列 如 下： | | 委員會 | 審 | 計 | 薪 | 酬 | 提 | 名 | | --- | --- | --- | --- | --- | --- | --- | --- | | 董 事 | | 委員會 | | | 委員會 | | 委員會 | | 羅劍輝 | | – | | 成 | 員 | | – | | 邰 洋 | | 成 | 員 | | – | 成 | 員 | | 仲人前 | | 成 | 員 | | – | | – | | 黃思樂 | | 主 | 席 | 主 | 席 | 成 | 員 | | 徐 達 | | 成 | 員 | | – | 成 | 員 | | 張建磊 | | 成 | 員 | 成 | 員 | 主 | 席 | IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公 司） （股份代號：1931） 香 港 董事名單及其角色與職能 二零二五年十月二十日 | 林賢雅 | | 執行董事兼總經理 | | --- | --- | --- | | 陳兆基 | | 執行董事 | | 羅 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公 司） （股份代號：1931） 董事調任 及 變更董事委員會組成 董事調任 華 檢 醫 療 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）謹 此 宣 佈， 邰 洋 女 士 已 由 本 公 司 獨 立 非 執 行 董 事（「董 事」）調 任 為 執 行 董 事，自 二 零 二 五 年 十 月 二 十 日 起 生 效（「調 任」）。 邰 女 士 之 履 歷 載 列 如 下： 邰洋女士，31歲，自 二 零 二 五 年 七 月 一 日 起 擔 任 獨 立 非 執 行 董 事。邰 女 士 於 二 零 一 六 年 七 月 畢 業 於 北 京 外 國 語 大 學，獲 得 管 理 學 學 士 學 位。彼 於 二 零 二 四 ...

Major Events - Four Seasons Pharmaceutical (00460) invests in Swiss Suisselle to accelerate global medical aesthetics business expansion [1] - Basilea Pharmaceutica-B (02616) to announce Phase I dose-escalation clinical data for PD-1/VEGF/CTLA-4 triple antibody and latest research design for ROR1 ADC [1] - Hengrui Medicine (01276) subsidiary receives drug clinical trial approval notice [1] - Huajian Medical (01931) acquires U.S. property and establishes U.S. subsidiary ETHK BANK to promote stablecoins and intellectual property securitization in the U.S. [1] - China National Pharmaceutical Group (01177): TQB2102 "HER2 dual antibody ADC" included in breakthrough therapy designation program [1] Operating Performance - 361 Degrees (01361): Retail sales of 361° main brand products in Q3 increased by approximately 10% year-on-year [1] - Xinhua Insurance (01336) expects net profit attributable to shareholders for the first three quarters to increase by 45% to 65% year-on-year [1] - Country Garden (02007) achieved contract sales amounting to approximately 2.58 billion yuan in September [1] - Dekang Agriculture and Animal Husbandry (02419) sold approximately 7.55 million pigs and generated sales revenue of approximately 14.28 billion yuan in the first nine months [1] - Longfor Group (00960) achieved total contract sales amount of 50.75 billion yuan in the first nine months [1]

Company News - Yuanshan Group (00551.HK) reported a cumulative operating income of approximately $6.017 billion for the first nine months, a decrease of 1% year-on-year [2] - Baoshan International (03813.HK) recorded a cumulative operating income of 12.903 billion yuan for the first nine months, down 7.7% year-on-year [2] - Longyuan Power (00916.HK) achieved a cumulative power generation of 56,546,706 MWh in the first nine months, a decline of 0.53% year-on-year; excluding the impact of thermal power, there was a year-on-year increase of 13.81%, with wind power up 5.30% and solar power up 77.98% [2] Financial Performance - Qinhuangdao Port Co., Ltd. (03369.HK) reported a total throughput of 317 million tons for the first nine months, an increase of 5.56% year-on-year [3] - New China Life Insurance (01336.HK) expects net profit attributable to shareholders for the first three quarters to be between 29.986 billion yuan and 34.122 billion yuan, representing a year-on-year growth of 45% to 65% [3] - Jiangshan Holdings (00295.HK) reported a total power generation of approximately 238,787 MWh for the first nine months, a decrease of 4.83% year-on-year [3] - Morning News Technology (02000.HK) reported an unaudited revenue of 270 million HKD for the first nine months, down 7.6% year-on-year [3] - Dekang Agriculture and Animal Husbandry (02419.HK) sold approximately 7.5509 million pigs in the first nine months, with sales revenue of approximately 14.277 billion yuan [3] Drug Approvals and Developments - Hengrui Medicine (01276.HK) received a clinical trial approval notice for SHR-A2102, a targeted Nectin-4 antibody-drug conjugate (ADC) developed in-house; global sales for similar products are expected to reach approximately $1.949 billion in 2024 according to EvaluatePharma [3] - Hutchison China MediTech (00013.HK) plans to announce FRUSICA-2 registration study data at the 2025 European Society for Medical Oncology annual meeting [3] - CSPC Pharmaceutical Group (01093.HK) had its new drug application for Idaglutide α injection accepted by the National Medical Products Administration [3] Corporate Actions - Huazhen Medical (01931.HK) announced the acquisition of U.S. properties and the establishment of a U.S. subsidiary, ETHK BANK, to promote stablecoins and intellectual property securitization in the U.S. [3] - Lihigh Holdings (08472.HK) plans to invest 24 million HKD in cryptocurrency and commodities [3] - Hisense Home Appliances (00921.HK) and its subsidiaries subscribed to a financial product from Jingu Trust worth 1.739 billion HKD [3] Real Estate Performance - New Town Development (01030.HK) reported cumulative contract sales of 15.050 billion yuan for the first nine months, a decrease of 52.72% year-on-year [3] - Longfor Group (00960.HK) achieved total contract sales of 50.75 billion yuan in the first nine months [3] - CIFI Holdings Group (00884.HK) reported cumulative contract sales of approximately 13.06 billion yuan for the first nine months [3] - Ronshine China Holdings (03301.HK) reported contract sales of 3 billion yuan for the first nine months, down 45.3% year-on-year [3] - Yuzhou Group (01628.HK) reported cumulative sales of 4.913 billion yuan for the first nine months [3] - Yida China (03639.HK) reported contract sales of approximately 572 million yuan for the first nine months, down 24.74% year-on-year [3] Financing and Buyback Activities - Geely Automobile (00175.HK) was approved to issue debt financing instruments totaling no more than 10 billion yuan [3] - HSBC Holdings (00005.HK) repurchased 1.58 million HKD worth of shares at prices ranging from 102.2 to 103.77 HKD [3] - Xiaomi Group-W (01810.HK) repurchased 400 million HKD worth of shares at prices ranging from 47.82 to 50.55 HKD [3] - Shoucheng Holdings (00697.HK) repurchased 890 million HKD worth of shares at prices ranging from 2.21 to 2.27 HKD [3]

Core Viewpoint - The company has recently completed the acquisition of a property in Irvine, California, for a total cost of $4.365 million and established a wholly-owned subsidiary in Colorado to facilitate its operations in North America related to stablecoins and intellectual property securitization in the medical and innovative pharmaceutical sectors [1] Group 1: Company Developments - The company acquired a property in Orange County, California, for $4.365 million [1] - A wholly-owned subsidiary, ETHKBANK Inc., was registered in Colorado to support the company's North American market activities [1] Group 2: Market Performance - As of October 13, 2025, the company's stock closed at HKD 8.88, down 4.62%, with a trading volume of 1.641 million shares and a turnover of HKD 14.6533 million [1] - The company has a market capitalization of HKD 15.069 billion, ranking second in the pharmaceutical commercial sector [1] Group 3: Financial Metrics - Key financial metrics for the company compared to the industry average are as follows: - ROE: 4.69% (industry average: 0.84%), ranking 6th [1] - Market capitalization: HKD 15.069 billion (industry average: HKD 5.112 billion), ranking 2nd [1] - Revenue: HKD 3.079 billion (industry average: HKD 78.621 billion), ranking 4th [1] - Net profit margin: 3.02% (industry average: 3.11%), ranking 4th [1] - Gross profit margin: 22.02% (industry average: 24.95%), ranking 5th [1] - Debt ratio: 42.78% (industry average: 41.64%), ranking 6th [1]

Core Viewpoint - The company has completed the acquisition of a property in Irvine, California, for $4.365 million, and established a wholly-owned subsidiary, ETHK BANK, to enhance its operations in the North American market, focusing on stablecoin and intellectual property securitization [1][2]. Group 1: Property Acquisition - The acquired property, located at 9840 Irvine Center Drive, spans approximately 4,960 square feet and includes a two-story office building of about 9,920 square feet, designed for both office and research purposes [2]. - This property will serve as the company's strategic headquarters in the U.S., supporting the development of stablecoin public chain technology and intellectual property securitization, creating a hub for connecting global innovative assets with capital markets [2]. Group 2: ETHK BANK - ETHK BANK will act as the global operational platform for the company's stablecoin and intellectual property securitization business, managing core business directions including stablecoin licensing and compliance framework establishment [3]. - The company is pursuing a federal payment stablecoin issuer license under the U.S. GENIUS Act and plans to apply for a national trust bank license to create a compliant operational system [3]. - The company is developing an innovative stablecoin architecture that supports the generation of stablecoins pegged to the U.S. dollar through real-world asset collateral, aiming to provide a transparent and sustainable digital asset yield solution [3]. Group 3: Key Project Cooperation - The company has signed a strategic cooperation agreement with Transcenta Holding Limited for the tokenization of innovative drug pipeline assets valued at approximately $1.5 billion, with ETHK BANK leading the initiative [5]. - This project focuses on cutting-edge research in cancer treatment, providing a transparent and professional channel for global investors to access medical assets [5]. Group 4: Future Outlook - The acquisition of the U.S. property and the establishment of ETHK BANK signify the company's strategic upgrade towards becoming a global leader in stablecoin and high-tech intellectual property capital operations [6]. - The company aims to integrate on-chain financial infrastructure with the real economy, aligning with global digital economy trends and potentially opening new growth pathways [6]. - The board believes these initiatives reflect the company's core philosophy of transforming knowledge into capital, ensuring long-term stable returns for shareholders through compliant capital operations and innovative practices [6].

Core Viewpoint - The company has completed the acquisition of a property in Irvine, California, for a total consideration of $4.365 million, and established a wholly-owned subsidiary, ETHKBANK, to enhance its operations in the North American market focusing on stablecoin and intellectual property securitization [1][2]. Group 1 - The acquired property will serve as the company's strategic headquarters in the U.S., supporting the development of stablecoin public chain technology and intellectual property securitization [2]. - The property spans approximately 4,960 square feet (about 0.113 acres) and includes a two-story office building of around 9,920 square feet, designed for both office and research purposes [1]. - The establishment of ETHKBANK aims to create a platform for efficient and transparent conversion of intangible asset values, connecting global innovative assets with capital markets [2]. Group 2 - The company plans to integrate its existing RWA-related business operations from mainland China and Hong Kong into ETHKBANK, optimizing global resource allocation and risk management [2]. - The strategic upgrade towards becoming a leading operator in stablecoin and high-tech intellectual property capital management is expected to align with global trends in digital economy and financial technology innovation [2]. - The board believes that these initiatives will open new growth pathways and enhance the value extraction and efficient circulation of high-quality global assets [2].

Group 1 - The company has completed the acquisition of a property in Irvine, California for a total price of $4.365 million [1] - A wholly-owned subsidiary, ETHKBANK Inc., has been established in Colorado to facilitate stablecoin, medical, and intellectual property securitization transactions in North America [1][2] - The acquisition and establishment of ETHKBANK are strategic moves to enhance global business collaboration and create sustainable long-term value for shareholders and investors [1][2] Group 2 - The property will serve as the company's strategic headquarters in the U.S., focusing on stablecoin public chain technology development and intellectual property securitization [2] - The company plans to integrate its existing RWA-related businesses from mainland China and Hong Kong into ETHKBANK for optimized resource allocation and effective risk management [2] - The board believes that these initiatives will position the company as a leading operator in stablecoin and high-tech intellectual property capital, promoting the integration of blockchain financial infrastructure with the real economy [2]